BeyondSpring Inc. (BYSI) |
|
0.7465 -0.004 (-0.47%)
|
09-28 16:00 |
|
Open: |
0.7262 |
Pre. Close: |
0.75 |
|
High:
|
0.77 |
Low:
|
0.7112 |
|
Volume:
|
31,122 |
Market Cap:
|
29(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:49:27 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1  One year: 1.1 |
| Support: |
Support1: 0.71 Support2: 0.59 |
| Resistance: |
Resistance1: 0.85 Resistance2: 0.94 |
| Pivot: |
0.84 |
| Moving Average: |
MA(5): 0.76 MA(20): 0.86
MA(100): 1.04 MA(250): 1.24 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 17 %D(3): 17.2 |
| RSI: |
RSI(14): 33.1 |
| 52-week: |
High: 3.45 Low: 0.54 |
| Average Vol(K): |
3-Month: 38 (K) 10-Days: 31 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BYSI ] has closed above bottom band by 15.1%. Bollinger Bands are 38.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.77 - 0.78 |
0.78 - 0.78 |
|
Low:
|
0.7 - 0.7 |
0.7 - 0.71 |
|
Close:
|
0.74 - 0.75 |
0.75 - 0.75 |
|
Company Description |
|
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York. |
Headline News |
Thu, 28 Sep 2023
BeyondSpring and Leading Cancer Center to Present Poster at ... - BioSpace
Wed, 20 Sep 2023
DatChat Inc Announces Reverse Stock Split and Focus on Privacy ... - Best Stocks
Thu, 07 Sep 2023
BeyondSpring to Participate in the R.W. Baird's 2023 Global - GlobeNewswire
Tue, 20 Jun 2023
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson ... - GlobeNewswire
Tue, 18 Apr 2023
BeyondSpring Provides Business Update and Reports Year End ... - GlobeNewswire
Tue, 20 Dec 2022
Individual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as well - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
2.385e+007 (%) |
|
% Held by Institutions
|
29.6 (%) |
|
Shares Short
|
1,970 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.701e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
756.4 |
|
Return on Equity (ttm)
|
-36.5 |
|
Qtrly Rev. Growth
|
1.35e+006 |
|
Gross Profit (p.s.)
|
-0.59 |
|
Sales Per Share
|
-1826.36 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
-0.85 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.93e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
